Skip to main content

Tagged With "Press Release"

Blog Post

AAFA Thanks President Trump for Highlighting America’s Need for Affordable Health Care

AAFA Community Services ·
On behalf of the more than 60 million Americans with asthma and allergies – many of whom depend on life-saving medications – the Asthma and Allergy Foundation of America (AAFA) thanks President Trump for including pre-existing conditions and affordable health care in his State of the Union address.
Blog Post

FDA Approves Dupixent® for Moderate-to-Severe Atopic Dermatitis in Adolescents

AAFA Community Services ·
Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has approved Dupixent® (dupilumab) for adolescent patients 12 to 17 years of age with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. Dupixent can be used with or without topical corticosteroids.
×
×
×
×